Details for Patent: 8,080,551

Which drugs does patent 8,080,551 protect, and when does it expire?

Patent 8,080,551 protects CABENUVA KIT, COMPLERA, EDURANT, JULUCA, and ODEFSEY, and is included in five NDAs.

This patent has one hundred and ninety-five patent family members in forty countries.

Summary for Patent: 8,080,551

Title:	HIV inhibiting pyrimidines derivatives
Abstract:	HIV replication inhibitors having formula (I) defined herein are disclosed. Pharmaceutical compositions containing the HIV replication inhibitors; the use of the HIV replication inhibitors in the treatment of HIV; and processes for preparing the HIV replication inhibitors are also disclosed.
Inventor(s):	Guillemont; Jerome Emile Georges (Andre, FR), Palandijian; Patrice (Louviers, FR), De Jonge; Marc Rene (Tilburg, NL), Koymans; Lucien Maria Henricus (Retie, BE), Vinkers; Hendrik Maarten (Antwerp, BE), Daeyaert; Frederik Frans Desire (Beerse, BE), Heeres; Jan (Vosselaar, BE), Van Aken; Koen Jeanne Alfons (Kortrijk, BE), Lewi; Paulus Joannes (Turnhout, BE), Janssen; Paul Adriaan Jan (Vosselaar, BE), Arts, legal representative; Frank Xavier Jozef Herwig (Beerse, BE)
Assignee:	Janssen Pharmaceutica N.V. (BE)
Application Number:	11/474,855
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,080,551
Patent Claim Types: see list of patent claims	Compound; Composition; Process; Formulation; Device;

Drugs Protected by US Patent 8,080,551

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-001	Jan 21, 2021		RX	Yes	Yes			Y	Y
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-002	Jan 21, 2021		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011		RX	Yes	Yes			Y	Y
Janssen Prods	EDURANT	rilpivirine hydrochloride	TABLET;ORAL	202022-001	May 20, 2011		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 8,080,551

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	01203090	Aug 13, 2001
	02077748	Jun 10, 2002

International Family Members for US Patent 8,080,551

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	1610
African Regional IP Organization (ARIPO)	2109
African Regional IP Organization (ARIPO)	2296
African Regional IP Organization (ARIPO)	2487